Loading…
← CockpitCompetitor Analysis › 6523.T PHC Holdings Corp.Open in the cockpit ↗

PHC Holdings Corp.6523.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Japanese maker of blood glucose monitors and diagnostics, spun off from Panasonic's healthcare division.

≈ Japan's version of a smaller Abbott (diabetes care/diagnostics)Momentum strong 74
Mkt cap
$1.02B
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$9.17M
20-day average traded
Fwd P/E
7.5×
forward earnings
ROIC−WACC
+0.3 pp
WACC 5.5%
Hurdle
-8 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · JPY¥1,286
1D-1.1%
1W-8.4%
1M-5.4%
3M-9.1%
6M+33.5%
YTD+15.7%
1Y+25.3%
ATR %5.3%
52w lowhigh24.1% off high

What PHC does

Japanese maker of blood glucose monitors and diagnostics, spun off from Panasonic's healthcare division.

Gets much of its income from Ascensia, the diabetes-care business bought from Bayer in 2016, whose meters feed recurring test-strip sales, while laboratory instruments and hospital systems add a steadier second line. Originally Panasonic's healthcare arm, it passed to the private-equity investor KKR in 2014 and listed in 2021.

In one line: Japan's version of a smaller Abbott (diabetes care/diagnostics).

Products and services

  • Blood glucose monitoring systems
  • Point-of-care diagnostics
  • Life sciences instruments

Customers

  • Diabetes patients/pharmacies
  • Hospitals/clinics

Where it sits in the supply chain

  • Health care
  • Diabetes care and diagnostics
  • Blood glucose monitors, diagnostic…

What could go right

  • Rising global diabetes prevalence

What could go wrong

  • Pricing pressure on test strips
  • Competition from CGM makers

Moat: narrow (installed base, brand, regulatory licence). Installed meter base creates recurring test-strip sales; regulatory approvals are a barrier to entry.

Headquarters: Tokyo, Japan · Founded: 2014 · Employees: 8,647

Named competitors

  • Abbott (FreeStyle) private or unlisted
  • Roche Diagnostics private or unlisted
  • Arkray private or unlisted

PHC at a glance

Size PHC (6523.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.02B, the 729th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,286 on 18 Nov 2026.

Performance Over six months the shares gained 33.5%, against -7.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 2.7% over the last twelve months (peer median +11.0%); the operating margin is 8.0% (peer median 11.0%).

Valuation It trades at 7.5× forward earnings against a peer median of 18.7× (2nd cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.3 points above its cost of capital (5.5% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 20266523.T 133Peer median 92
Six months, rebased to 100: PHC against the median of its 20 peers (local-currency closes).

PHC financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥371B¥364B¥362B¥354B¥356B
Revenue growth—+1%+2%-1%—
Gross profit¥173B¥148B¥148B¥140B¥150B
EBITDA¥56.7B¥47.7B¥49.8B¥36.2B¥57.5B
Net income¥14.4B¥492M¥10.5B-¥12.9B-¥3.22B
Free cash flow¥42.3B¥33.4B¥30.3B¥26.7B¥9.86B
Capital expenditure¥9.30B¥9.09B¥11.6B¥14.6B¥11.5B
Total debt¥222B¥251B¥269B¥300B¥307B

Quarterly statements and history in the cockpit →

PHC competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%301021600055300685EUZCSTL300206CBLLIRMD300143SIBN68862230110177302141503046SFLATEC77806523.T6-month return →1-month return →
Up and to the right = strong over both horizons. PHC is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×300685EUZ300206IRMD3001433011017730IART214150SFLATEC77806523.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PHC is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%301021300685EUZCSTL300206IRMD3001437730IART2141503046SFL6523.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PHC is the large dot.

PHC competitors and peer comparison

How PHC compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PHC against its 20 peers (data as of 18 Nov 2026)
Measure6523.TPeer medianRank in peer set
1-month return-5.4%-1.9%9th lowest of 21
6-month return+33.5%-7.9%5th highest of 20
Distance from 52-week high-24.1%-28.9%8th highest of 21
Revenue growth (TTM)+2.7%+11.0%5th lowest of 20
Operating margin8.0%11.0%7th lowest of 21
Forward P/E7.5×18.7×2nd cheapest of 14
Growth the price implies (Req g, 7 yrs)-4.0%6.9%3rd least demanding of 14
Growth delivered (Del g)+3.5%+11.7%2nd lowest of 14
Hurdle (Req g minus delivered)-7.6 pp-3.0 pp4th least demanding of 14
ROIC minus cost of capital+0.3 pp+3.1 pp9th lowest of 20
EV / EBITDA6.1×9.1×cheapest of 11
Net debt / EBITDA3.2×-0.2×3rd most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a

Questions

Who are PHC's main competitors?
Named competitors: Abbott (FreeStyle) (private or unlisted), Roche Diagnostics (private or unlisted), Arkray (private or unlisted). The cockpit's measured peer set (industry) also includes Inno Laser Technology (301021.SZ), Beijing Wandong Medical Technology (600055.SS), Amoy Diagnostics (300685.SZ), Eckert & Ziegler (EUZ.DE), Castle Biosciences (CSTL), Edan Instruments (300206.SZ).
Is PHC expensive compared with its peers?
On forward p/e it trades at 7.5× against a peer median of 18.7×, 2nd cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has PHC stock performed?
Over six months to 18 Nov 2026 the shares returned +33.5% against -7.9% for the median peer; over one year +25.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.